88 results
8-K
EX-99.1
GLYC
GlycoMimetics Inc
27 Mar 24
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
9:00am
equivalents of $41.8 million, compared to $47.9 million as of December 31, 2022.
R&D Expenses: The company’s research and development expenses decreased … to $5.3 million for the quarter ended December 31, 2023, compared to $5.9 million for the fourth quarter of 2022. Research and development expenses
PRE 14A
GLYC
GlycoMimetics Inc
22 Mar 24
Preliminary proxy
5:00pm
of Sumitomo Pharma Oncology, Inc. (and its predecessor, Boston Biomedical, Inc.), an oncology drug research and development company … clinical experience allow him to make particularly valuable contributions to our research and development efforts, while his public company board experience
8-K
EX-99.1
GLYC
GlycoMimetics Inc
3 Nov 23
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
8:35am
to $47.9 million as of December 31, 2022.
R&D Expenses: The company’s research and development expenses increased to $5.3 million for the quarter ended … :
Research and development expense
General and administrative expense
Total costs and expenses
Loss from operations
Interest income
Net loss
8-K
EX-99.1
ig6kd4ywkxjx2rmjp
2 Aug 23
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
8:35am
8-K
EX-99.1
nsnhcbnu
3 May 23
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023
8:36am
8-K
EX-99.1
4i64a7
9 Nov 22
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022
8:15am
8-K
EX-99.1
5rrvw 50z07qqbqjfp
3 Aug 22
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022
8:25am
424B5
bjgtbqlq
28 Apr 22
Prospectus supplement for primary offering
5:01pm
8-K
EX-99.1
bqdft2fzk1botiwt8 8x
28 Apr 22
GlycoMimetics Reports Highlights and Financial Results
8:30am